CytomX Therapeutics, Inc. (CTMX) reported a net loss of $20.4 million or $0.15 per share for fiscal 2025, compared to a profit of $31.9 million or $0.38 per share last year. Full-year revenues declined to $76.2 million from $138.1 million in fiscal 2024.
As of December 31, 2025, cash equivalents and investments totaled $137.1 million, compared to $100.6 million last year. Shares of the company traded at $4.87. on volume of 2,864,938. The company has a market capitalization of $1.32 billion.
A detailed analysis of CytomX Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25 first appeared on Alphastreet.
